Literature DB >> 24333302

Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.

Antonio Coppola1, Annarita Tagliaferri2, Gabriele Calizzani3, Fabio Candura3, Massimo Franchini4, Carlo Ruosi1, Giuliano Grazzini3, Giovanni Di Minno1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24333302      PMCID： PMC3853986          DOI： 10.2450/2013.016s

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  64 in total

Review 1.  Plasma-derived medicinal products in Italy: information sources and flows.

Authors:  Monica Lanzoni; Claudia Biffoli; Fabio Candura; Gabriele Calizzani; Stefania Vaglio; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 2.  Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.

Authors:  Marcel Levi; Marjolein Peters; Harry R Büller
Journal:  Crit Care Med       Date:  2005-04       Impact factor: 7.598

3.  Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

Authors:  N S Key; L M Aledort; D Beardsley; H A Cooper; G Davignon; B M Ewenstein; G S Gilchrist; J C Gill; B Glader; W K Hoots; C T Kisker; J M Lusher; C G Rosenfield; A D Shapiro; H Smith; E Taft
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

4.  A retrospective postlicensure survey of FEIBA efficacy and safety.

Authors:  D Dimichele; C Négrier
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

5.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Authors:  Jan Astermark; Sharyne M Donfield; Donna M DiMichele; Alessandro Gringeri; Steven A Gilbert; Jennifer Waters; Erik Berntorp
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

Review 6.  Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: Is there a foetal risk?

Authors:  Nadia Léticée; Cécile Kaplan; Didier Lémery
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-08-01       Impact factor: 2.435

7.  A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.

Authors:  E Santagostino; M E Mancuso; A Rocino; G Mancuso; F Scaraggi; P M Mannucci
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 8.  Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.

Authors:  Man-Chiu Poon; Rainer Zotz; Giovanni Di Minno; Zvika S Abrams; Jens B Knudsen; Yves Laurian
Journal:  Semin Hematol       Date:  2006-01       Impact factor: 3.851

9.  Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.

Authors:  Khan Kavakli; Mike Makris; Bulent Zulfikar; Elizabeth Erhardtsen; Zvi S Abrams; Gili Kenet
Journal:  Thromb Haemost       Date:  2006-04       Impact factor: 5.249

Review 10.  Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.

Authors:  A Gringeri; P M Mannucci
Journal:  Haemophilia       Date:  2005-11       Impact factor: 4.287
View more
  3 in total

Review 1.  Public expenditure for plasma-derived and recombinant medicinal products in Italy.

Authors:  Monica Lanzoni; Fabio Candura; Gabriele Calizzani; Claudia Biffoli; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Plasma-derived medicinal products: demand and clinical use.

Authors:  Giuliano Grazzini; Pier Mannuccio Mannucci; Fabrizio Oleari
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 3.  Uncovered needs in the management of inherited bleeding disorders in Italy.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.